Mounjaro Cost in Rhode Island: Prices, Insurance, and Savings in 2026

What Mounjaro Costs Without Insurance

Eli Lilly's list price for Mounjaro has been widely reported at roughly $1,023 per month across all six dose strengths (2.5 mg through 15 mg), sold as a carton of four weekly pens. Because tirzepatide has no generic competitor yet, cash prices at Rhode Island pharmacies (CVS, Walgreens, independent pharmacies, and warehouse-club pharmacies) tend to cluster close to that list price, with discount cards occasionally shaving off a modest amount in a given month.

Treat any specific dollar figure in this article, including the one above, as a starting point rather than a quote. Cash prices move with manufacturer pricing decisions, pharmacy markups, and discount-card terms that change without much notice. Confirm the current price directly with the dispensing pharmacy before counseling a patient on affordability.

Tirzepatide received FDA approval in May 2022 for type 2 diabetes under the brand name Mounjaro, based in part on the SURPASS trial program. The FDA-approved prescribing information documents the approved indication, dosing schedule, and safety information and is the most reliable reference for what the drug is approved to treat and how it is dosed. Tirzepatide also has a separate FDA approval as Zepbound for chronic weight management, at the same molecule but marketed under a different brand and label.

In the SURPASS-2 trial (N=1,879), tirzepatide 15 mg produced greater HbA1c reduction and greater weight loss over 40 weeks than semaglutide 1 mg in adults with type 2 diabetes. That trial is one of the reasons demand for tirzepatide has remained high, and high demand is part of why the out-of-pocket price matters so much to patients paying cash.

Rhode Island Medicaid Coverage

Rhode Island Medicaid, administered through the Executive Office of Health and Human Services (EOHHS), can cover Mounjaro with prior authorization for patients with a documented type 2 diabetes diagnosis. As in most state Medicaid programs, prior authorization for a GLP-1/GIP agent typically involves a recent HbA1c value and documentation that the patient has tried, or cannot tolerate, first-line therapy such as metformin. Exact PA criteria, required documentation, and out-of-pocket costs for approved claims should be confirmed directly with EOHHS or the patient's Medicaid managed-care plan, since these details are updated periodically and are not fully documented in the clinical sources behind this article.

Coverage for weight management alone, without a type 2 diabetes diagnosis, is generally not available through Rhode Island Medicaid as of this writing. This mirrors the position of most state Medicaid programs nationally. Legislation such as the Treat and Reduce Obesity Act has been proposed in Congress to expand federal coverage of anti-obesity medications but has not become law, so Medicaid coverage for obesity-only indications should not be assumed without checking current EOHHS policy.

Commercial Insurance in Rhode Island

Major insurers operating in Rhode Island, including Blue Cross Blue Shield of Rhode Island (BCBSRI), UnitedHealthcare, Aetna, Cigna, and Neighborhood Health Plan of Rhode Island, have included Mounjaro on at least some plan formularies, but coverage terms differ by employer group, plan tier, and year. Prior authorization, step therapy showing a trial of metformin or another oral agent, and a documented HbA1c value are common requirements for the type 2 diabetes indication. Some plans place Mounjaro on a specialty tier with higher cost-sharing.

Patients denied coverage can request a peer-to-peer review with their plan and, if the denial stands, can pursue Rhode Island's external appeal process through the Office of the Health Insurance Commissioner (OHIC). The specific state statute governing denial notices was not independently confirmed for this draft and should be verified with OHIC or Rhode Island General Law before it is cited to a patient.

Because formulary status, tier placement, and cost-sharing change from plan year to plan year, and can differ between two plans sold by the same insurer, a patient's own plan documents or member services line are the only reliable way to confirm current coverage.

How the Manufacturer Savings Card Works

Eli Lilly has offered a Mounjaro savings card that lowers the out-of-pocket cost for commercially insured patients at participating pharmacies, including in Rhode Island. In general, savings cards of this type work by having the patient's commercial insurance process first, with the card applied afterward as a secondary payer that reduces the remaining copay, up to a program maximum that resets annually. Federal law prohibits manufacturer copay cards from being used by patients on government insurance, so Medicaid, Medicare Part D, TRICARE, and VA beneficiaries are not eligible for this type of program regardless of manufacturer.

The exact copay floor, per-fill maximum, and annual cap for the current version of the card change periodically and are set by the manufacturer, not by this article. Confirm current terms directly on the manufacturer's savings card page or with the prescribing office before telling a patient what they will pay.

If a patient's plan does not cover Mounjaro at all (a hard denial or non-formulary status), a manufacturer savings card typically cannot apply, because there is no primary insurance claim for it to supplement. In that situation, appealing the denial or exploring compounded tirzepatide or a patient assistance program are the more relevant next steps.

Compounded Tirzepatide: Cost and Legal Status

Compounded tirzepatide is available in Rhode Island through state-licensed 503A compounding pharmacies filling a valid, patient-specific prescription. It is commonly reported as substantially cheaper than brand-name Mounjaro, though the exact price varies by compounding pharmacy and should be confirmed directly with that pharmacy rather than assumed from a general figure.

The legal basis for 503A compounding is federal. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a licensed pharmacy can prepare a patient-specific compounded version of an FDA-approved drug under certain conditions. Tirzepatide became widely available for compounding in part because it appeared on the FDA's drug shortage list during parts of 2023 and 2024. The FDA later announced that tirzepatide products were no longer in shortage. Once a drug is off the shortage list, the legal basis for many compounders to keep producing near-copies of it narrows, and federal enforcement activity in this area has continued to evolve since that announcement. Anyone relying on compounded tirzepatide, or advising a patient who is, should check the current FDA shortage status and any recent enforcement guidance rather than assuming the 2023 to 2024 shortage-era rules still apply unchanged.

Rhode Island has not been confirmed to impose state-level compounding restrictions beyond federal requirements, but that should be verified with the Rhode Island Board of Pharmacy rather than assumed. Patients considering a compounding pharmacy should confirm it holds a current Rhode Island Board of Pharmacy license and current USP 797/800 sterile and non-sterile compounding compliance. Quality and sourcing practices vary meaningfully between compounders. Compounded tirzepatide is typically dispensed as a multi-dose vial requiring the patient to draw up and inject the correct volume, rather than the pre-filled pen used with brand-name Mounjaro, which is a practical difference some patients weigh heavily.

Combining tirzepatide, compounded or brand, with other medications should be reviewed with a prescriber or pharmacist; checking with a pharmacist about drug interactions can be a helpful starting point for that conversation.

Telehealth Access in Rhode Island

Rhode Island permits telehealth prescribing of Mounjaro. A licensed provider can prescribe tirzepatide after a video or audio visit without requiring an in-person appointment first, consistent with the state's telehealth parity framework for non-controlled substances.

Multiple telehealth platforms prescribe Mounjaro or arrange compounded tirzepatide for Rhode Island patients, typically charging a consultation fee separate from the medication cost. Reported fee ranges vary by platform and change over time, so a specific number was not retained here; check the platform's current pricing directly.

Access to obesity pharmacotherapy remains limited relative to the number of patients who could benefit from it. Commentators have discussed the gap between the scale of obesity-related disease and the small share of eligible patients who actually receive drug treatment, and have argued that expanding access, including through telehealth, is one way to help close that gap. Any specific figure or claim along these lines should be checked against a current, directly relevant source before being quoted.

Ways to Lower the Cost

Not every option applies to every patient, and none of these guarantee a specific price.

Use a manufacturer savings card, if commercially insured. For patients whose plan covers Mounjaro, a savings card is typically the largest single reducer of out-of-pocket cost. Confirm current eligibility and terms on the manufacturer's site.

Ask about a formulary exception. If a plan covers Zepbound but not Mounjaro, or the reverse, a prescriber can submit a formulary exception request with supporting clinical documentation. Rhode Island's OHIC external review process is a further option if an internal appeal is denied.

Compare pharmacies. Brand-name pricing tends to be fairly uniform, but some independent pharmacies and warehouse-club pharmacies price specialty medications somewhat differently than large chains. A direct price check at two or three local pharmacies is the only reliable way to know.

Consider compounded tirzepatide. This is generally the lowest cash price for patients without coverage, with the legal and quality caveats described above.

Ask about manufacturer patient assistance. Eli Lilly has operated a patient assistance program providing free medication to qualifying uninsured patients under an income threshold, verified through the prescriber. Current eligibility rules and income cutoffs should be confirmed on the manufacturer's site, not assumed from prior years' terms.

Clinical and advocacy groups, including endocrinology professional societies, have published statements arguing that prior authorization burden and high cost-sharing are meaningful barriers to evidence-based obesity treatment. The precise wording of any such statement should be checked directly before it is quoted.

Dosing and Why Price Doesn't Change With Dose

Mounjaro is started at 2.5 mg weekly for four weeks, then increased to 5 mg weekly, with further increases in 2.5 mg increments roughly every four weeks up to a maximum of 15 mg weekly, based on tolerability and response. This schedule is documented in the FDA-approved label.

Unlike many medications, the list price does not change by dose strength. A carton of 2.5 mg pens and a carton of 15 mg pens carry the same list price, so patients who titrate up to a higher maintenance dose do not face an additional list-price penalty for doing so.

In the SURMOUNT-1 trial (N=2,539), adults without type 2 diabetes lost substantially more body weight on tirzepatide than on placebo over 72 weeks, with a clear dose-response relationship across the 5 mg, 10 mg, and 15 mg maintenance doses studied. That dose-response pattern is part of why prescribers often titrate toward the higher end of the range when patients tolerate it.

Verification Checklist: What's Stable vs. What Needs a Fresh Check

Some facts about Mounjaro rarely change. Others, especially anything involving Rhode Island insurers, Medicaid, specific pharmacies, or cash prices, can be outdated within months. Use this checklist before repeating a specific number or coverage rule to a patient.

Stable facts (federal approval and clinical evidence; unlikely to change often)

• Tirzepatide's FDA-approved indication and dosing schedule: confirm against the FDA label or the patient information sheet available from the manufacturer or pharmacy.
• Trial-level efficacy data (SURPASS-2, SURMOUNT-1): confirm against the primary trial publications, not a secondary summary.
• The federal legal framework for 503A compounding: confirm against FDA's Section 503A guidance.
• The general mechanics of manufacturer copay cards and why government-insured patients cannot use them: this is a stable feature of federal anti-kickback law, not a plan-specific detail.

Date-sensitive facts (verify before every use, ideally at the point of care)

• Current tirzepatide shortage status: check the FDA's drug shortage database directly; do not assume a 2023 to 2024 shortage status still applies.
• Brand-name Mounjaro list price and Rhode Island retail cash price: confirm with the dispensing pharmacy or manufacturer, not a cited article.
• Compounded tirzepatide pricing at a specific pharmacy: confirm directly with that compounding pharmacy, including its current Rhode Island Board of Pharmacy license status.
• Rhode Island Medicaid prior authorization criteria and member cost-sharing: confirm with EOHHS or the patient's Medicaid managed-care plan.
• A specific commercial plan's formulary status, tier, and PA or step-therapy requirements: confirm with that plan's current member documents or member services line.
• Manufacturer savings card copay floor, per-fill maximum, and annual cap: confirm on the manufacturer's current savings card page.
• Patient assistance program income thresholds and enrollment steps: confirm on the manufacturer's current program page.
• Telehealth platform consultation fees: confirm on that platform's current pricing page.

A simple rule of thumb: if a fact traces back to an FDA approval, a published trial, or a federal statute, it changes slowly. If a fact traces back to what a specific payer, pharmacy, or state Medicaid program will actually charge or approve this month, treat it as perishable and verify it fresh.

References

1. Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503-515. PubMed
2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. PubMed
3. U.S. Food and Drug Administration. Mounjaro (tirzepatide) prescribing information, label. accessdata.fda.gov
4. U.S. Food and Drug Administration. Human drug compounding: Section 503A. FDA.gov